usage, and adverse events were monitored. Data was analyzed at baseline, 3 months, 6 months, 12 months, 24 months, 36 months, and 48 months after treatment. A scripted patient questionnaire was completed over the phone to assess patient satisfaction.
INTRODUCTION AND OBJECTIVES:
In a large, blinded, multicenter, randomized trial (WATER) (30-80cc), Aquablation, an ultrasound-guided, robotically executed waterjet ablative procedure demonstrated better outcomes in larger glands compared to TURP. These observations identified the need to assess the safety and efficacy of performing Aquablation in men with larger prostate glands (80-150cc) (WATER II). Herein we report the 6-month outcomes.
METHODS: Between September and December 2017, 101 men with moderate-to-severe benign prostatic hyperplasia symptoms and prostate volume of 80-150cc underwent Aquablation in a prospective multicenter international clinical trial. Baseline demographics and standardized postoperative management parameters were carefully recorded in a central independently monitored database. Functional and safety outcomes were assessed at 6 months postoperatively.
RESULTS: Mean prostate volume was 107cc (range 80-150). Mean operative time was 37 minutes with a mean Aquablation resection time of 8 minutes (range 3-17 minutes) and a mean of 1.8 treatment passes. The average length of stay following the procedure was 1.6 days (range same day-6 days). Bleeding complications were recorded in 10 (9.9%) patients during the index procedure hospitalization prior to discharge and included six (5.9%) perioperative transfusions. The primary safety endpoint (Clavien-Dindo Grade 2 or higher or any Grade 1 event resulting in persistent disability) at 3 months occurred in 45.5% of men, which met the study design goal of less than 65% (p<0.0001). Mean IPSS improved from 23.2 (þ/-6.3) at baseline to 11.5 (þ/-6.6) at 1 month and 6.7 (þ/-5.1) at 3 months meeting the study's primary efficacy endpoint goal (p<0.0001). IPSS at 6 months was 5.9 (þ/-5.4), a 75% reduction.
Maximum urinary flow rate increased from 8.7 to 18.8 cc/sec (an improvement of 10.4 cc/sec, p<0.0001) and post-void residual decreased from 131 at baseline to 47 at 6 months (a 91-cc decrease). 81% of the sexually active men in this study (107cc baseline prostate size) maintained their ejaculatory function. At 6 months, PSA reduced from 7.1 (þ/-5.9) ng/mL to 4.0 (3.9þ/-) ng/ mL, a 44% reduction.
CONCLUSIONS: With 6 months follow-up, Aquablation is safe and effective in treating men with larger prostates (80-150cc) without significant increase in procedure or resection time. The one year follow up will be completed in December 2018 and those results will be available for the 2019 AUA Congress. ClinicalTrials.gov number, NCT03123250.
Presentation on behalf of the Water II investigators 
Holmium Laser Enucleation of the Prostate (HoLEP) has emerged as a standard of care in the treatment of benign prostatic hyperplasia (BPH). This operation entails two distinct parts -laser enucleation of the adenoma from the surrounding prostatic capsule followed by morcellation of this enucleated prostate from within the distended bladder. HoLEP is associated with a steep learning curve and multiple studies have reported bladder injury sustained during the morcellation portion of the operation as a potential catastrophic complication, occurring in up to 6% of cases. The risk of this complication increases when there is poor intravesical visualization due to either a bloody field or poor optics. The aim of this study is to report the novel use of bladder ultrasound during morcellation to assist with safe completion of HoLEP.
METHODS: Enucleation is performed using a 26-French continuous flow scope, off-set laser bridge with a laser stabilization catheter, and a 550mm holmium laser fiber. Once the median, left, and right lateral lobes have been enucleated, the outer sheath is removed and the nephroscope is inserted to facilitate morcellation. Under dual inflow irrigation, the Piranha morcellator (Richard Wolf, Knittlingen, Germany) is then introduced and set to the manufacturer's recommended settings of 1,500 rpm. A 3.5-MHz convex abdominal ultrasound transducer (Hitachi Prosound Alpha 7; Hitachi Aloka Medical America, Wallingford, CT) under B-mode is used to visualize the bladder, predominantly in the sagittal orientation. Morcellation proceeds under simultaneous ultrasound and direct cystoscopic guidance.
RESULTS: The distended bladder is visualized concurrently with the ultrasound console and via the nephroscope as the Piranha engages the adenoma and begins morcellation. Once the adenoma is engaged, the operator then drops their hands to place the morcellator in the center of the bladder. Ultrasound provides real-time confirmatory feedback and serves as an additional guide as to the location of the morcellator in relation to the adenoma and bladder.
CONCLUSIONS: Here we demonstrate the use of intraoperative bladder ultrasound as a visual aid to assist during the morcellation portion of HoLEP. This proof of concept demonstrates that ultrasound can be an additional tool to utilize during difficult cases when cystoscopic Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e163
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